Therapeutic strategies to improve control of hypertension

Journal of Hypertension

Volumn 31, Issue SUPPL. 1, 2013, Pages

  Armario, Pedro ^a   Waeber, Bernard ^b  

^a Moises Broggi Hospital Sant Joan d'Espì   (Spain)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

arterial hypertension; combination therapy; control hypertension; therapeutic strategies

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MINOXIDIL;

ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CLINICAL INERTIA; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETIC PATIENT; EUROPE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; MEDICAL PARAMETERS; MONOTHERAPY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIAL CLASS; VASCULAR DISEASE;

EID: 84873695464     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835d2c6c     Document Type: Article

References (42)

1. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. Br Med J 2009; 338:1245-1253.
2. Wolf-Maier K, Cooper RS, Kramer H, Banegqas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada and the United States. Hypertension 2004; 43:10-17.
3. Banegas JR, López-Garc?́a E, Dallongeville J, Guallar E, Halcox JP, Borghi C, et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe. the EURIKA study. Eur Heart J 2011; 32:2143-2152.
4. Chiao E, Sobolski J, Krienke R, Wong KS, Dastani HB, Nightengale B. High-risk patients with hypertension: are we doing enough? J Am Soc Hypertens 2008; 2:385-392.
5. Mar?́n R, Fernández-Vega F, Gorostidi M, Ruilope LM, D?́ez J, Praga M, et al. Blood pressure control in patients with chronic renal insufficiency in Spain: a cross-sectional study. J Hypertens 2006; 24:395-402.
6. Prugger C, Keil U, Wellmann J, de Bacquer D, de Backer G, Ambrosio B, et al. Blood pressure control and knowledge of target blood pressure in coronary patients across Europe: results from the EUROASPIRE III survey. J Hypertens 2011; 29:1641-1648.
7. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. J Am Med Assoc 2010; 303:2043-2050.
8. Gee ME, Bienek A, McAlister FA, Robitaille C, Joffres M, Tremblay MS, et al. Factors associated with lack of awareness and uncontrolled high blood pressure among Canadian adults with hypertension. Can J Cardiol 2012; 28:375-382.
9. Campbell NR, Sheldon T. The Canadian effort to prevent and control hypertension: can other countries adopt Canadian strategies? Curr Opin Cardiol 2010; 25:366-372.
10. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119:3028-3035.
11. Okonofua EC, Simpson KN, Jesri A, Rehman SU, Durkalski VL, Egan BM. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals. Hypertension 2006; 47:345-351.
12. Redón J, Brunner HR, Ferri C, Hilgers KF, Kolloch R, van Montfrans G. Practical solutions to the challenges of uncontrolled hypertension: a white paper. J Hypertens 2008; 26 (Suppl 4):S1-S14.
13. Bailey JE, Wan JY, Ghani MA, Cushman WC. Antihypertensive medicaton adherence, ambulatory visits, and risk of stroke and death. J Gen Intern Med 2010; 25:495-503.
14. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29:610-618.
15. Simpson SH, Eurich DT, Majundar SR, Padwal RS, Tsuyuki RT, Varney J, Johnson JA. A meta-analysis of the association between adherence to drug therapy and mortality. Br Med J 2006; 333:15.
16. Laufs U, Retting-Ewen V, Böhm M. Strategies to improve drug adherence. Eur Heart J 2011; 32:264-268.
17. Crowley MJ, Smith VA, Olsen MK, Danus S, Oddone EZ, Bosworth HB, Powers BJ. Treatment intensification in a hypertension telemanagement trial. Clinical inertia or good clinical judgment? Hypertension 2011; 58:552-558.
18. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors. A systematic review and meta-analysis of randomized trials. Arch Intern Med 2011; 171:1441-1453.
19. Clark CE, Smith LFP, Taylor RS, Campbell JL. Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis. Br Med J 2010; 341:c3995.
20. Pladevall M, Brotons C, Gabriel R, Arnau A, Suárez C, de la Figuera M, et al. Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (The COM99 Study). Circulation 2010; 122:1183-1191.
21. Hill MN, Miller NH, DeGeest S, on behalf of the American Society of Hypertension Writing Group. Adherence and persistence with taking medication to control high blood pressure. J Am Soc Hypertens 2011; 5:56-63.
22. Kronish IM, Woodward M, Sergie Z, Ogedegbe G, Falzon L, Mann DM. Meta-analysis. Impact of drugs class on adherence to antihypertensive. Circulation 2011; 123:1611-1621.
23. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11 000 participants from 42 trials. Am J Med 2009; 122:290-300.
24. Banegas JR, Segura J, Sobrino J, Rodr?́guez-Artalejo F, de la Sierra A, de la Cruz JJ, et al. Effectiveness of blood pressure control outside in the medical setting. Hypertension 2007; 49:62-68.
25. Ferrari P, and the National Coordinators for the Reasons for not Intensifying Antihypertensive Treatment (RIAT) trial. Reason for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. J Hum Hypertens 2009; 23:151-159.
26. Salvetti M, Muiesan ML, Paini A, Monteduro C, Agabiti-Rosei C, Aggiusti C, et al. Left ventricular hypertrophy and renal dysfunction during antihypertensive treatment adversely affects cardiovascular prognosis in hypertensive patients. J Hypertens 2012; 30:411-420.
27. Volpe M, Battistoni A, Tocci G, Agabiti-Rosei E, Catapano AL, Coppo R, et al. Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. J Hypertens 2012; 30: 1056-1064.
28. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice guidelines for the management of arterial hypertension. ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762.
29. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363:2022-2031.
30. Staessen JA, Thijs L, Fagard R, Celis H, Birkenhäger WH, Bulpitt CJ, et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22:847-857.
31. Kostis WJ, Thijs L, Richart T, Kostis JB, Staessen JA. Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications. Hypertension 2010; 56:1060-1068.
32. Waeber B, Feihl F, Ruilope LM. Fixed-dose combinations as initial therapy for hypertension. A review of approved agents and a guide to patient selection. Drugs 2009; 69:1761-1776.
33. Corrao G, Nicotra F, Parodi A, Zambon A, Heiman F, Merlino L, et al. Cardiovascular protection by initial and subsequent combination of antihypertensive drugs in daily life practice. Hypertension 2011; 58: 566-572.
34. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120:713-719.
35. Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SAE, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension. A cluster randomized, controlled trial. Hypertension 2009; 53:646-653.
36. Makani H, Bangalores S, Romero J, Wever-Pinzón O, Messerli FH. Effect of renin-angiotesin system blockade on calcium channel blocker-associated peripheral edema. Am J Med 2011; 124:128-135.
37. Calhoun DA, Laconurcière Y, Chiang YT, Glazer RD. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide. A randomized clinical trial. Hypertension 2009; 54:32-39.
38. Oparil S, Melino M, Lee J, Fernández V, Heyrman R. Triple therapy con olmesartanmedoximil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: the TRINIT multicenter, randomized, double-blind, 12-week, parallel-group study. Clin Ther 2010; 32:1252-1269.
39. De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902.
40. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A Scientific Statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
41. Roush GC, Holford TR, Guddari AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events. Systematic review and network meta-analysis. Hypertension 2012; 59:1110-1117.
42. Marrs JC. Spironolactone management of resistant hypertension. Ann Pharmacother 2010; 44:1762-1769.